Lorne Tyrrell
Biochemistry
KMT Hepatech
Canada
Biography
D. Lorne Tyrrell, OC, AOE, MD, PhD, FRCP, FRSC is a Professor of Medicine, Biochemistry and Medical Microbiology and Immunology, and the Founding Director of the Li Ka Shing Institute of Virology, University of Alberta. As the co-founder, Vice President and Chief Scientific Officer at KMT Hepatech, Inc., he leads the development and refinement of animal model. Dr. Tyrrell holds the CIHR/GSK (Canadian Institutes for Health Research / GlaxoSmithKline) Chair in Virology. He received his Doctor of Medicine with Distinction from the University of Alberta and PhD in Pharmacology from Queen’s University in Ontario. His work on the development of antiviral therapy resulted in the licensing of the first oral antiviral agent to treat chronic hepatitis B infection – lamivudine – in 1998. Today, lamivudine is licensed in over 170 countries worldwide for the treatment of HBV. Dr. Tyrrell is a recipient of more than 40 Awards and Honors, author and co-author of 18 book chapters, 177 peer reviewed papers, and over 50 patents.
Research Interest
Biochemistry
